Современные подходы к консервативной терапии поликистозной болезни почек
- Авторы: Руденко Т.Е.1, Бобкова И.Н.1, Ставровская Е.В.1
-
Учреждения:
- ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
- Выпуск: Том 91, № 6 (2019)
- Страницы: 116-123
- Раздел: Статьи
- URL: https://journals.rcsi.science/0040-3660/article/view/59011
- DOI: https://doi.org/10.26442/00403660.2019.06.000299
- ID: 59011
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Татьяна Евгеньевна Руденко
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Email: atatianaer@yandex.ru
к.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета; тел.: +7(499)246-61-76; e-mail: atatianaer@yandex.ru; ORCID: 0000-0002-1296-4494 Москва, Россия
Ирина Николаевна Бобкова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета Москва, Россия
Екатерина Викторовна Ставровская
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета Москва, Россия
Список литературы
- Нефрология. Национальное руководство. Под ред. Н.А. Мухина. М.: ГЭОТАР-Медиа; 2009. 720 с. [Nefrologiya. Natsional’noe rukovodstvo.
- Collins A.J, Foley R.N, Herzog C, Chavers B, Gilbertson D, Ishani A, Johansen K, Kasiske B, Kutner N, Liu J, St. Peter W, Ding S, Guo H, Kats A, Lamb K, Li S, Li S, Roberts T, Skeans M, Snyder J, et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis. 2013;61(1 suppl 1):e1-e480. doi: 10.1053/j.ajkd.2012.11.031
- Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta - analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018;13(1):e0190430. doi: 10.1371/journal.pone.0190430
- Willey C.J, Blais J.D, Hall A.K, Krasa H, Makin A, Czerwiec F. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32:1356-63. doi: 10.1093/ndt/gfw240
- Ong A.C, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385 (9981):1993-2002. doi: 10.1016/S0140-6736(15)60907-2
- Porath B, Gainullin V.G, Cornec-Le Gall E, et al. Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal - dominant polycystic kidney and liver disease. Am J Human Genet. 2016;98(6):1193-207. doi: 10.1016/j.ajhg.2016.05.004
- Bergmann C, Senderek J, Ellenwindelen F, et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal - recessive polycystic kidney disease (ARPKD). Kidney Int. 2005;67:829-48.
- Chebib F, Torres V. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney. CJASN. 2018;13(11):1765-76. doi: 10.2215/CJN.03960318
- Singla V, Reiter J. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science. 2006;313:629-33. doi: 10.1126/science.1124534
- Pan J, Seeger-Nukpezah T, Golemis E.A. The role of the cilium in normal and abnormal cell cycles: Emphasis on renal cystic pathologies. Cell Mol Life Sci. 2013;70:1849-74. doi: 10.1007/s00018-012-1052-z
- Kottgen M, Walz G. Subcellular localization and trafficking of polycystins. Iflugers Arch. 2005;451(1):286-93. doi: 10.1007/s00424-005-1417-3
- Nauli S.M, Alenghat F.J, Luo Y, Williams E, Vassilev P, Li X, Elia A.E, Lu W, Brown E.M, Quinn S.J, Ingber D.E, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003;33(2):129-37. doi: 10.1038/ng1076
- Nauli S.M, Pala R, Kleene S.J. Calcium channels in primary cilia. Curr Opin Nephrol Hypertens. 2016;25(5):452-8. doi: 10.1097/MNH.0000000000000251
- Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol Cell Biol. 2007;8(11):880-93. doi: 10.1038/nrm2278
- Montesano R, Ghzili H, Carrozzino F, Rossier B.C, Feraille E. cAMP-dependent chloride secretion mediates tubule enlargement and cyst formation by cultured mammalian collecting duct cells. Am J Physiol Renal Physiol. 2009;296(2):F446-57. doi: 10.1152/ajprenal.90415.2008
- Devuyst O, Torres V.E. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens. 2013;22(4):459-70. doi: 10.1097/MNH.0b013e3283621510
- Terryn S, Ho T.A, Beauwens R.C, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta. 2011;1812:1314-21. doi: 10.1016/j.bbadis.2011.01.011
- Bankir L, Bichet D/G. Polycystic kidney disease: An early urea - selective urine - concentrating defect in ADPKD. Nat Rev Nephrol. 2012;8:437-9. doi: 10.1038/nrneph.2012.139
- Torres V, Grantham J.J, Chapman A.B, Mrug M, Bae K.T, King B.F, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:640-7. doi: 10.2215/CJN.03250410
- Meijer E, Bakker S.J, van der Jagt E.J, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:361-8. doi: 10.2215/cjn.04560510
- Boertien W.E, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012;27:4131-7. doi: 10.1093/ndt/gfs070
- Boertien W.E, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420-9. doi: 10.1053/j.ajkd.2012.08.038
- Wang X, Wu Y, Ward C.J, Harris P.C, Torres V.E. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102-8. doi: 10.1681/asn.2007060688
- Grantham J.J, Torres V.E. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol. 2016;12:667-77. doi: 10.1038/nrneph.2016.135
- Mc Ewan P, Bennett Wilton H, Ong A.C.M, Orskov B, Sandford R, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol. 2018;19:37. doi: 10.1186/s12882-017-0804-2
- Rahbari-Oskoui F.F, Landsittel D, Torres V.E. Relationship between renal complications and total kidney volume in autosomal dominant polycystic kidney disease from the Consortium for Radiologic Imaging of Polycystic Kidney Disease Cohort. Presented at: Kidney Week 2013; November 5-10, 2013; Atlanta, GA [abstract]. J Am Soc Nephrol. 2013;24:687A.
- Alam A, Dahl N, Lipschutz J, Rossetti S, Smith P, Sapir D, Weinstein J, Mc Farlane P, Bichet D. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. Am J Kidney Dis. 2015;66(4):564-76. doi: 10.1053/j.ajkd.2015.01.030
- Soroka S, Alam A, Bevilacqua M, Girard L.P, Komenda P, Loertscher R, Mc Farlane P, Pandeya S, Tam P, Bichet D.G. Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Can J Kidney Health Dis. 2018;5:1-15. doi: 10.1177/2054358118801589
- Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A, Rodríguez-Pérez J.C, Sans L, Torra R. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(Suppl 4):iv95-105. doi: 10.1093/ndt/gfu186
- Weimbs T, Shillingford J.M, Torres J, Kruger S.L, Bourgeois B.C. Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clin Kidney J. 2018 Dec;11(Suppl 1):i27-i38. doi: 10.1093/ckj/sfy089
- Bichet D.G. Central vasopressin: dendritic and axonal secretion and renal actions. Clin Kidney J. 2014;7:242-7. doi: 10.1093/ckj/sfu050
- Torres V.E, Higashihara E, Devuyst O, Chapman A.B, Gansevoort R.T, Grantham J.J, Perrone R.D, Ouyang J, Blais J.D, Czerwiec F.S. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016;11(5):803-11. doi: 10.2215/CJN.06300615
- Gansevoort R.T, van Gastel M.D, Chapman A.B. Copeptin, a surrogate for vasopressin, predicts disease progression and tolvaptan treatment efficacy in ADPKD. Results of the TEMPO 3:4 trial. J Am Soc Nephrol. 2016;27:34A.
- Torres V.E, Chapman A.B, Devuyst O, Gansevoort R.T, Perrone R.D, Koch G, Ouyang J, Mc Quade R.D, Blais J.D, Czerwiec F.S, Sergeyeva O. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.; REPRISE Trial Investigators. N Engl J Med. 2017;377:1930-42. doi: 10.1056/NEJMoa1710030
- Torres V.E, Chapman A.B, Devuyst O, Gansevoort R.T, Perrone R.D, Dandurand A, Ouyang J, Czerwiec F.S, Blais J.D. Multicenter, open - label, extension trial to evaluate the long - term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33(3):477-89. doi: 10.1093/ndt/gfx043
- Baur B.P, Meaney C.J. Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy. 2014;34(6):605-16. doi: 10.1002/phar.1421
- Blair H.A, Keating G.M. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs. 2015;75(15):1797-806. doi: 10.1007/s40265-015-0475-x
- Poch E, Rodas L, Blasco M, Molina A, Quintana L. An update on tolvaptan for autosomal dominant polycystic kidney disease. Drugs Today (Barc). 2018;54(9):519-33. doi: 10.1358/dot.2018.54.9.2776624
- Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17:2220-7. doi: 10.1681/asn.2006030251
- Hopp K, Wang X, Ye H, Irazabal M.V, Harris P.C, Torres V.E. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol. 2015;308:F261-F266. doi: 10.1152/ajprenal.00345.2014
- Barash I, Ponda M.P, Goldfarb D.S, Skolnik E.Y. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5:693-97. doi: 10.2215/cjn.04180609
- Higashihara E, Nutahara K, Tanbo M, Kurahashi T, Marunouchi T, Takahashi H, Wallace D.P. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant. 2014;29:1710-9. doi: 10.1093/ndt/gfu093
- Neijenhuis M.K, Gevers T.J, Nevens F, Hogan M.C, Torres V.E, Kievit W, Drenth J.P. Somatostatin analogues improve health - related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo - controlled trials. Aliment Pharmacol Ther. 2015;42(5):591-8. doi: 10.1111/apt.13301
- Hopp K, Hommerding C.J, Wang X, Ye H, Harris P.C, Torres V.E. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015;26:39-47. doi: 10.1681/ASN.2013121312
- Wahl P.R, Serra A.L, Le Hir M, Molle K.D, Hall M.N, Wuthrich R.P. Inhibition of mTOR with sirolimus slows disease progression in Han. SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006 Mar;21(3):598-604. doi: 10.1093/ndt/gfl181
- Tao Y, Kim J, Schrier R, Edelstein C.L. Rapamycin markedly slows disease progression in rat model of polycystic kidney disease. J Am Soc Nephrol. 2005;16(1):46-51. doi: 10.1681/ ASN.2004080660
- Serra A.L, Poster D, Kistler A.D, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820-9. doi: 10.1056/NEJMoa0907419
- Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl W.H, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt K.U. Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2010;363(9):830-40. doi: 10.1056/nejmoa1003491
- Rajani R, Pastor-Soler N.M, Hallows K.R. Role of AMP activated protein kinase in kidney tubular transport, metabolism, and disease. Curr Opin Nephrol Hypertens. 2017;26:375-83. doi: 10.1097/mnh.0000000000000349
- Takiar V, Nishio S, Seo-Mayer P, King J.D. Jr, Li H, Zhang L, Karihaloo A, Hallows K.R, Somlo S, Caplan M.J. Activating AMP activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108:2462-7. doi: 10.1073/pnas.1011498108
- Seliger S, Abebe K, Hallows K, Miskulin D, Perrone R, Watnick T, Bae K. A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am J Nephrol. 2018;47:352-60. doi: 10.1159/000488807
- Grantham J, Torres V, Chapman A, Guay-Woodford L, Bae K, King B, Wetzel L, Baumgarten D, Kenney P, Harris P, Klahr S, Bennett W, Hirschman G, Meyers C, Zhang X, Zhu F, Miller J. Volume Progression in Polycystic Kidney Disease. N Engl J Med. 2006;354:2122-30. doi: 10.1056/nejmoa054341
- Torres V.E, Abebe K.Z, Chapman A.B, Schrier R.W, Braun W.E, Steinman T.I, Winklhofer F.T, Brosnahan G, Czarnecki P.G, Hogan M.C, Miskulin D.C, Rahbari-Oskoui F.F, Grantham J.J, Harris P.C, Flessner M.F, Moore C.G, Perrone R.D; HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267-76. doi: 10.1056/NEJMoa1402686
- Schrier R.W, Abebe K.Z, Perrone R.D, Torres V.E, Braun W.E, Steinman T.I, Winklhofer F.T, Brosnahan G, Czarnecki P.G, Hogan M.C, Miskulin D.C, Rahbari-Oskoui F.F, Grantham J.J, Harris P.C, Flessner M.F, Bae K.T, Moore C.G, Chapman A.B; HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255-66. doi: 10.1056/NEJMoa1402685
- Irazabal M, Abebe K, Bae K, Perrone R, Chapman A, Schrier R, Yu A, Braun W, Steinman T, Harris P, Flessner M, Torres V. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017;32(11):1857-65. doi: 10.1093/ndt/gfw294
- Schrier R, Mc Fann K, Jonson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison T. Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycystic Kidney Disease: Results of a Seven-Year Prospective Randomized Study. J Am Soc Nephrol. 2002;13(7):1733-9. doi: 10.1097/01.asn.0000018407.60002.b9
- Klahr S, Breyer J.A, Beck G.J, Dennis V.W, Hartman J.A, Roth D, Steinman T, Wang S.R, Yamamoto M.E. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5(12):2037-47.
- Torres V.E, Grantham J.J, Chapman A.B, Mrug M, Bae K.T, King B.F.Jr, Wetzel L.H, Martin D, Lockhart M.E, Bennett W.M, Moxey-Mims M, Abebe K.Z, Lin Y, Bost J.E; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(3):640-7. doi: 10.2215/CJN.03250410
- Amro O.W, Paulus J.K, Noubary F, Perrone R.D. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial. Am J Kidney Dis. 2016 Dec;68(6):882-91. doi: 10.1053/j.ajkd.2016.07.023
- Girardat-Rotar L, Puhan M.A, Braun J, Serra A.L. Long - term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. J Nephrol. 2018;31(1):87-94. doi: 10.1007/s40620-017-0396-8
- Orth S.R, Stockmann A, Conradt C, et alю Smoking as a risk factor for end - stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926-31. doi: 10.1046/j.1523-1755.1998.00067.x
- Nowak K.L, You Z, Gitomer B, Brosnahan G, Torres V.E, Chapman A.B, Perrone R.D, Steinman T.I, Abebe K.Z, Rahbari-Oskoui F.F, Yu A.S.L, Harris P.C, Bae K.T, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018;29(2):571-8. doi: 10.1681/ASN.2017070819
- Cadnapaphornchai M.A, George D.M, Mc Fann K, Wang W, Gitomer B, Strain J.D, Schrier R.W. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9(5):889-96. doi: 10.2215/CJN.08350813
- Bolignano D, Palmer S.C, Ruospo M, Zoccali C, Craig J.C, Strippoli G.F. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2015;14(7):CD010294. doi: 10.1002/14651858.CD010294.pub2